Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Teekamp, P. Hagedoorn, B. G. Huijbers, D. Gjaltema, H. W. Frijlink, A. H. de Boer (Groningen, Netherlands). Comparison of the in vitro performance of originator and generic drug-combination dry powder inhalers. Eur Respir J 2013; 42: Suppl. 57, 714

Member's Comments

No comment yet.

Related content which might interest you: Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs comparator in paediatric asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Innovative dry powder inhaler (DPI) shows improved cost-effectiveness compared with current DPIs for asthma therapy in UK primary care Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Prevalence of serious post-training inhaler technique errors made by device-naïve patients using three different dry powder inhalers (DPIs) Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 In vitro validation of the use of a spacer with an extrafine beclomethasone/formoterol formulation Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Inspiratory flow resistance of marketed dry powder inhalers (DPI) Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques Year: 2016 Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Evaluation of acceptability, efficacy and safety of a novel dry powder inhaler in patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 70s Year: 2007 Clinical evaluation of fluticasone/formoterol twice daily delivered via a single dose dry powder inhaler in patients with persistent asthma Source: International Congress 2016 – Asthma management Year: 2016 Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Inhaler preference comparing two alternative dual bronchodilator regimens Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Pharmacokinetic studies for the estimation of bioequivalence of two DPIs containing budesonide and formoterol Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015